國立虎尾科技大學 |

Biomarker Discovery in the Developing World: Dissecting the Pipeline for Meeting the Challenges

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Biomarker Discovery in the Developing World: Dissecting the Pipeline for Meeting the Challenges/ edited by Sanjeeva Srivastava.
其他作者:	Srivastava, Sanjeeva.
面頁冊數:	XI, 118 p. 28 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Cancer research. -
電子資源:	https://doi.org/10.1007/978-81-322-2837-0
ISBN:	9788132228370

Biomarker Discovery in the Developing World: Dissecting the Pipeline for Meeting the Challenges
Biomarker Discovery in the Developing World: Dissecting the Pipeline for Meeting the Challenges[electronic resource] /edited by Sanjeeva Srivastava. - 1st ed. 2016. - XI, 118 p. 28 illus. in color.online resource.

Chapter 1: Exigencies of biomarker research in developing world: A focus on the dearth of biobanking resources -- Chapter 2: Geographic pervasiveness of cancer: Prospects of novel biomarker and therapeutic research in developing countries using OMICs approaches -- Chapter 3: Omics data processing and analysis -- Chapter 4: Basics of mass spectrometry and its applications in biomarker discovery -- Chapter 5: Angel Philanthropy and Crowdfunding to Accelerate Cancer Research in Developing World -- Chapter 6: Delivering on the Promise of Bioeconomy in Developing World: Link it with Social Innovation and Education -- Chapter 7: Role of proteomics in characterization of biosimilar products -- Chapter 8: Regulatory norms and intellectual property rights for biomarker research.

This book is oriented towards post-graduates and researchers with interest in proteomics and its applications in clinical biomarker discovery pipeline. Biomarker discovery has long been the research focus of many life scientists globally. However, the pipeline starting from discovery to validation to regulation as a diagnostic or therapeutic molecule follows a complex trajectory. This book aims to provide an in-depth synopsis on each of these developmental phases attendant to biomarker “life cycle” with emphasis on the emerging and significant role of proteomics. The book begins with a perspective on the role of biorepositories and need for biobanking practices in the developing world. The next chapter focuses on disease heterogeneity in context to geographical bias towards susceptibility to the disease and the role of multi-omics techniques to devise disruptive innovations towards biomarker discovery. Chapter 3 focuses on various omics-based platforms that are currently being used for biomarker discovery, their principles and workflow. Mass spectrometry is emerging as a powerful technology for discovery based studies and targeted validation. Chapter 4 aims at providing a glimpse of the basic workflow and considerations in mass spectrometry based studies. Rapid and aptly targeted research funding has often been deemed as one of the decisive factors enabling excellent science and path breaking innovations. With theneed for sophistication required in multi-omics research, Chapter 5 focuses on innovative funding strategies such as crowdfunding and Angel philanthropy. Chapter 6 provides the latest advances in education innovation, the premise and reality of bioeconomy especially in a specific context of the developing world, not to mention the new concept of “social innovation” to link biomarkers with socially responsible and sustainable applications. Chapter 7, in ways similar to biomarkers, discusses the biosimilars as a field that has received much focus and prominence recently due to their immense potential in clinical and pharmaceutical innovation literatures. The broader goal post-biomarker discovery is to translate their use in clinics. However, the road from bench-to-bed side is arduous and complex that is subject to oversight from various national and international regulatory bodies. Chapter 8 underscores these regulatory science considerations and provides a concise overview on intellectual property rights in biomarker discovery. Thus, this book contributed by eminent biomarker scientists, clinicians, translational researchers and social scientists holistically covers the various facets of the biomarker discovery journey from “cell to society” in developing world. The lessons learned and highlighted here are of interest to the life sciences community in a global and interdependent world.

ISBN: 9788132228370

Standard No.: 10.1007/978-81-322-2837-0doiSubjects--Topical Terms:

1253664
Cancer research.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

Biomarker Discovery in the Developing World: Dissecting the Pipeline for Meeting the Challenges
LDR:05033nam a22003975i 4500 001 979473
003 DE-He213
005 20200706080745.0
007 cr nn 008mamaa
008 201211s2016 ii | s |||| 0|eng d
020 $a 9788132228370 $9 978-81-322-2837-0
024 7 $a 10.1007/978-81-322-2837-0 $2 doi
035 $a 978-81-322-2837-0
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a Biomarker Discovery in the Developing World: Dissecting the Pipeline for Meeting the Challenges $h [electronic resource] / $c edited by Sanjeeva Srivastava.
250 $a 1st ed. 2016.
264 1 $a New Delhi : $b Springer India : $b Imprint: Springer, $c 2016.
300 $a XI, 118 p. 28 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Chapter 1: Exigencies of biomarker research in developing world: A focus on the dearth of biobanking resources -- Chapter 2: Geographic pervasiveness of cancer: Prospects of novel biomarker and therapeutic research in developing countries using OMICs approaches -- Chapter 3: Omics data processing and analysis -- Chapter 4: Basics of mass spectrometry and its applications in biomarker discovery -- Chapter 5: Angel Philanthropy and Crowdfunding to Accelerate Cancer Research in Developing World -- Chapter 6: Delivering on the Promise of Bioeconomy in Developing World: Link it with Social Innovation and Education -- Chapter 7: Role of proteomics in characterization of biosimilar products -- Chapter 8: Regulatory norms and intellectual property rights for biomarker research.
520 $a This book is oriented towards post-graduates and researchers with interest in proteomics and its applications in clinical biomarker discovery pipeline. Biomarker discovery has long been the research focus of many life scientists globally. However, the pipeline starting from discovery to validation to regulation as a diagnostic or therapeutic molecule follows a complex trajectory. This book aims to provide an in-depth synopsis on each of these developmental phases attendant to biomarker “life cycle” with emphasis on the emerging and significant role of proteomics. The book begins with a perspective on the role of biorepositories and need for biobanking practices in the developing world. The next chapter focuses on disease heterogeneity in context to geographical bias towards susceptibility to the disease and the role of multi-omics techniques to devise disruptive innovations towards biomarker discovery. Chapter 3 focuses on various omics-based platforms that are currently being used for biomarker discovery, their principles and workflow. Mass spectrometry is emerging as a powerful technology for discovery based studies and targeted validation. Chapter 4 aims at providing a glimpse of the basic workflow and considerations in mass spectrometry based studies. Rapid and aptly targeted research funding has often been deemed as one of the decisive factors enabling excellent science and path breaking innovations. With theneed for sophistication required in multi-omics research, Chapter 5 focuses on innovative funding strategies such as crowdfunding and Angel philanthropy. Chapter 6 provides the latest advances in education innovation, the premise and reality of bioeconomy especially in a specific context of the developing world, not to mention the new concept of “social innovation” to link biomarkers with socially responsible and sustainable applications. Chapter 7, in ways similar to biomarkers, discusses the biosimilars as a field that has received much focus and prominence recently due to their immense potential in clinical and pharmaceutical innovation literatures. The broader goal post-biomarker discovery is to translate their use in clinics. However, the road from bench-to-bed side is arduous and complex that is subject to oversight from various national and international regulatory bodies. Chapter 8 underscores these regulatory science considerations and provides a concise overview on intellectual property rights in biomarker discovery. Thus, this book contributed by eminent biomarker scientists, clinicians, translational researchers and social scientists holistically covers the various facets of the biomarker discovery journey from “cell to society” in developing world. The lessons learned and highlighted here are of interest to the life sciences community in a global and interdependent world.
650 0 $a Cancer research. $3 1253664
650 0 $a Proteomics. $3 581930
650 0 $a Infectious diseases. $3 1102043
650 0 $a Drug resistance. $3 872072
650 1 4 $a Cancer Research. $3 668358
650 2 4 $a Infectious Diseases. $3 668393
650 2 4 $a Drug Resistance. $3 782695
700 1 $a Srivastava, Sanjeeva. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1113337
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9788132228356
776 0 8 $i Printed edition: $z 9788132228363
776 0 8 $i Printed edition: $z 9788132238539
856 4 0 $u https://doi.org/10.1007/978-81-322-2837-0
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)